Moreover, the number of tumor‐infiltrating CD8 T cells in the MPN/CpG (low) and MPN/CpG (high) treatment groups was significantly higher than in other treatment groups, reaching 30.2% and 28.9% (Figure 5N). The gene discussed is CD8A; the disease is neoplasm.